Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.94 EUR | -2.02% | -3.72% | -45.43% |
Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.43% | 108M | |
+5.73% | 71.48B | |
+11.69% | 9.18B | |
-15.34% | 4.79B | |
+34.54% | 3.98B | |
+5.09% | 3.97B | |
+27.76% | 2.56B | |
-28.33% | 2.29B | |
-24.15% | 2.23B | |
+6.23% | 1.92B |
- Stock Market
- Equities
- AB Stock
- News AB Science
- AB Science Gets US FDA Nod To Resume Enrollment For Neurological Disease Drug Study